Novynette (Desogestrel, Ethinylestradiol)

Novynette is a combined oral contraceptive that acts on the hormonal regulation of the menstrual cycle.

• Contraception: Provides effective prevention of pregnancy when taken as directed.
• Menstrual cycle regulation: Helps to establish more predictable menstrual bleeding patterns.
• Acne improvement: Reduces androgen‑driven skin lesions in some women using the pill.
• Endometriosis symptom relief: Alleviates pain associated with endometriosis through hormonal suppression.
• Polycystic ovary syndrome (PCOS) management: Assists in regulating cycles and reducing hyperandrogenic symptoms.

• Desogestrel is a synthetic progestogen that binds to progesterone receptors, inhibiting the mid‑cycle luteinising hormone surge and preventing ovulation. Ethinylestradiol provides estrogenic activity that stabilises the endometrial lining, enhances contraceptive efficacy, and reduces breakthrough bleeding. Together, the two agents synergistically suppress the hypothalamic‑pituitary‑gonadal axis to maintain a controlled hormonal environment.

Novynette, like other combined oral contraceptives, may cause a range of adverse reactions.

Common Side Effects

• Nausea: Mild to moderate stomach upset, especially when starting therapy.
• Headache: Tension‑type or migraine‑like headaches.
• Breast tenderness: Temporary swelling or discomfort of breast tissue.
• Weight change: Slight increase or decrease in body weight.
• Mood changes: Fluctuations in mood or mild depressive symptoms.
• Spotting between periods: Light bleeding or spotting.

Serious or Rare Side Effects

• Venous thromboembolism: Blood clot formation in deep veins or lungs.
• Arterial thrombosis: Stroke or myocardial infarction, particularly in smokers over 35.
• Severe hypertension: Sudden, marked increase in blood pressure.
• Liver dysfunction: Jaundice or abnormal liver enzyme levels.
• Allergic reactions: Rash, itching, swelling, or anaphylaxis.
• Gallbladder disease: Inflammation or stones in the gallbladder.

Before prescribing Novynette, clinicians should evaluate individual risk factors and counsel patients on safe use.

• Smoking status: Avoid use in women over 35 who smoke due to increased cardiovascular risk.
• Cardiovascular history: Contraindicated in patients with a history of thromboembolic events, stroke, or myocardial infarction.
• Liver disease: Use with caution in patients with active liver disease or hepatic dysfunction.
• Hypertension: Monitor blood pressure regularly; discontinue if severe hypertension develops.
• Migraine with aura: Not recommended for women experiencing migraine with aura.
• Store at ambient temperature: Keep below 25 °C, in the original packaging, protected from moisture and direct sunlight.

Novynette may interact with several medicines, altering its effectiveness or increasing adverse event risk.

Major Interactions (Avoid)

• Antiepileptic drugs (e.g., carbamazepine, phenytoin): Reduce hormonal efficacy, increasing pregnancy risk.
• Rifampicin: Decreases plasma concentrations of both estrogen and progestin components.
• Certain HIV protease inhibitors (e.g., ritonavir): May increase estrogen levels, raising clot risk.

Moderate Interactions (Monitor Closely)

• Antibiotics (e.g., amoxicillin, tetracycline): May slightly lower contraceptive effectiveness.
• St. John’s wort: Potentially reduces hormone levels, requiring additional contraceptive measures.
• Antifungal azoles (e.g., fluconazole): Can increase estrogen exposure, warranting blood pressure monitoring.